CMap drugs of 10 μM are usually used to treat cancer cells and generate gene expression signatures, therefore the inability of other S100A4-inhibitory drugs to reverse HMGA2-driven gene signature might be due to the higher doses required for S100A4 inhibition (Table 4). Here, S100A4 is linked to cancer.